KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Gross Margin (2018 - 2025)

Historic Gross Margin for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2025 value amounting to 98.51%.

  • Ionis Pharmaceuticals' Gross Margin fell 6900.0% to 98.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 98.51%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 98.41% for FY2024, which is 4300.0% down from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Gross Margin is 98.51%, which was down 6900.0% from 98.51% recorded in Q2 2025.
  • Ionis Pharmaceuticals' Gross Margin's 5-year high stood at 99.49% during Q4 2021, with a 5-year trough of 96.45% in Q2 2022.
  • Its 5-year average for Gross Margin is 98.29%, with a median of 98.48% in 2023.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Gross Margin skyrocketed by 208200bps in 2021, and later plummeted by -19200bps in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Gross Margin stood at 99.49% in 2021, then fell by -2bps to 97.57% in 2022, then increased by 2bps to 99.06% in 2023, then fell by -1bps to 98.31% in 2024, then increased by 0bps to 98.51% in 2025.
  • Its Gross Margin stands at 98.51% for Q3 2025, versus 98.51% for Q2 2025 and 98.89% for Q1 2025.